APO RESEARCH · REPORT
Malignant Mesothelioma Therapeutic
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Product & engineering
Understand the product.
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
Selected research
Industry Research
Malignant Mesothelioma Therapeutic Industry Research Report 2026
Market perspective
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
The classification of Malignant Mesothelioma Therapeutic includes Pemetrexed, Cisplatin and others. The proportion of Pemetrexed in 2019 approaches 50%. Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%. Europe is the largest market, with a sales market share above 50% in 2019. Following Europe, Asia Pacific is the second largest sales place with the sales market share of above 1/5. Market competition is intense. Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
Read the full market overview
Report Scope
This report quantifies the global Malignant Mesothelioma Therapeutic market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Malignant Mesothelioma Therapeutic.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Malignant Mesothelioma Therapeutic Market by Company
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Malignant Mesothelioma Therapeutic Segment by Type
Pemetrexed
Cisplatin
Others
Malignant Mesothelioma Therapeutic Segment by Application
Pleural Mesothelioma
Peritoneal Mesothelioma
Others
Malignant Mesothelioma Therapeutic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Mesothelioma Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Malignant Mesothelioma Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Mesothelioma Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Malignant Mesothelioma Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pemetrexed
- Cisplatin
- Others
Applications
- Pleural Mesothelioma
- Peritoneal Mesothelioma
- Others
Companies covered
- Eli Lilly
- Teva
- Sanofi
- Bristol-Myers Squibb
- Pfizer
- Roche
- Merck
- Ono Pharmaceutical
- Mylan
- Fresenius Kabi
- Sun Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Malignant Mesothelioma Therapeutic by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Pemetrexed
- 2.2.3 Cisplatin
- 2.2.4 Others
- 2.3 Malignant Mesothelioma Therapeutic by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pleural Mesothelioma
- 2.3.3 Peritoneal Mesothelioma
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Malignant Mesothelioma Therapeutic Breakdown Data by Type
- 3.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Type (2021-2026)
- 3.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2027-2032)
4 Malignant Mesothelioma Therapeutic Breakdown Data by Application
- 4.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Application (2021-2026)
- 4.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2021-2032)
- 5.2 Global Malignant Mesothelioma Therapeutic Growth Trends by Region
- 5.2.1 Global Malignant Mesothelioma Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Malignant Mesothelioma Therapeutic Historic Market Size by Region (2021-2026)
- 5.2.3 Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2027-2032)
- 5.3 Malignant Mesothelioma Therapeutic Market Dynamics
- 5.3.1 Malignant Mesothelioma Therapeutic Industry Trends
- 5.3.2 Malignant Mesothelioma Therapeutic Market Drivers
- 5.3.3 Malignant Mesothelioma Therapeutic Market Challenges
- 5.3.4 Malignant Mesothelioma Therapeutic Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue
- 6.1.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue (2021-2026)
- 6.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2021-2026)
- 6.2 Global Malignant Mesothelioma Therapeutic Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Malignant Mesothelioma Therapeutic Head Office and Area Served
- 6.4 Global Malignant Mesothelioma Therapeutic Players, Product Type & Application
- 6.5 Global Malignant Mesothelioma Therapeutic Manufacturers Established Date
- 6.6 Global Malignant Mesothelioma Therapeutic Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Malignant Mesothelioma Therapeutic Market Size (2021-2032)
- 7.2 North America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Malignant Mesothelioma Therapeutic Market Size by Country (2021-2026)
- 7.4 North America Malignant Mesothelioma Therapeutic Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Malignant Mesothelioma Therapeutic Market Size (2021-2032)
- 8.2 Europe Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2021-2026)
- 8.4 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size (2021-2032)
- 9.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Malignant Mesothelioma Therapeutic Market Size (2021-2032)
- 10.2 South America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Malignant Mesothelioma Therapeutic Market Size by Country (2021-2026)
- 10.4 South America Malignant Mesothelioma Therapeutic Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size (2021-2032)
- 11.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eli Lilly
- 12.1.1 Eli Lilly Company Information
- 12.1.2 Eli Lilly Business Overview
- 12.1.3 Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.1.4 Eli Lilly Malignant Mesothelioma Therapeutic Product Portfolio
- 12.1.5 Eli Lilly Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.2.4 Teva Malignant Mesothelioma Therapeutic Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.3.4 Sanofi Malignant Mesothelioma Therapeutic Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Bristol-Myers Squibb
- 12.4.1 Bristol-Myers Squibb Company Information
- 12.4.2 Bristol-Myers Squibb Business Overview
- 12.4.3 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.4.4 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product Portfolio
- 12.4.5 Bristol-Myers Squibb Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.5.4 Pfizer Malignant Mesothelioma Therapeutic Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Roche
- 12.6.1 Roche Company Information
- 12.6.2 Roche Business Overview
- 12.6.3 Roche Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.6.4 Roche Malignant Mesothelioma Therapeutic Product Portfolio
- 12.6.5 Roche Recent Developments
- 12.7 Merck
- 12.7.1 Merck Company Information
- 12.7.2 Merck Business Overview
- 12.7.3 Merck Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.7.4 Merck Malignant Mesothelioma Therapeutic Product Portfolio
- 12.7.5 Merck Recent Developments
- 12.8 Ono Pharmaceutical
- 12.8.1 Ono Pharmaceutical Company Information
- 12.8.2 Ono Pharmaceutical Business Overview
- 12.8.3 Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.8.4 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product Portfolio
- 12.8.5 Ono Pharmaceutical Recent Developments
- 12.9 Mylan
- 12.9.1 Mylan Company Information
- 12.9.2 Mylan Business Overview
- 12.9.3 Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.9.4 Mylan Malignant Mesothelioma Therapeutic Product Portfolio
- 12.9.5 Mylan Recent Developments
- 12.10 Fresenius Kabi
- 12.10.1 Fresenius Kabi Company Information
- 12.10.2 Fresenius Kabi Business Overview
- 12.10.3 Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.10.4 Fresenius Kabi Malignant Mesothelioma Therapeutic Product Portfolio
- 12.10.5 Fresenius Kabi Recent Developments
- 12.11 Sun Pharmaceuticals
- 12.11.1 Sun Pharmaceuticals Company Information
- 12.11.2 Sun Pharmaceuticals Business Overview
- 12.11.3 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2021-2026)
- 12.11.4 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product Portfolio
- 12.11.5 Sun Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst